Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Qsymia Launch Includes Strategy To Overcome Medicare Hurdles

Executive Summary

Company reports several hundred prescribers have completed online training as part of the Risk Evaluation and Mitigation Strategy for the weight loss drug, which is moving toward a fourth-quarter entry into the marketplace.

You may also be interested in...



Vivus’ Qsymia Sales Still Slim, Even As Costs Bulge

The obesity drug maker is pulling out all the stops to make its drug more accessible to patients, but several roadblocks still stand in the way of the drug banking meaningful sales revenue. Meanwhile, the launch and a post-marketing trial of Qsymia are adding up in terms of cost.

Qsymia, Belviq Make Progress With Aetna, But Coverage Remains Long-Term Challenge

Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.

FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs

Agency offers perspective in New England Journal of Medicine that lays out the case for careful use of drugs in a space with medical need but a long history of products with toxic side effects.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel